Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 115 |
| Active Pipeline (Recruiting Now) | 71 (29) |
| Completed vs Stopped Early | 13 / 1 (0.9%) |
| Median Closed Actual Enrollment | 168 participants |
| Physical Hospital Site Disclosure | 99.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 8 |
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 6 |
| Shanghai East Hospital | Shanghai | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06406205 | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Qilu Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.